Publications

Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi B, Langer CJ. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020. PMID: 33069888

Brondfield S, Bochatay N, Perlis C. Developing a Community for Patients With Cancer Through Longer-Term Art Therapy. JCO oncology practice. 2020. PMID: 33052801

Basu A, Philip EJ, Dewitt B, Hanmer J, Chattopadhyay A, Yau C, Melisko ME, Esserman LJ. The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology. NPJ breast cancer. 2020. PMID: 33083531

Camargo JF, Lin RY, Natori Y, Anderson AD, Alencar MC, Wang TP, Morris MI, Komanduri KV. Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study. Blood advances. 2020. PMID: 32991718

Bernabe-Ramirez C, Velazquez AI, Olazagasti C, Bergerot CD, Bergerot PG, Soto-Perez-de-Celis E, Duma N. The HOLA COVID-19 Study: An International Effort to Determine How COVID-19 Has Impacted Oncology Practices in Latin America. Cancer cell. 2020. PMID: 33098754

Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S, Yeung J, Spinner MA, Lunning M, Inghirami G, Moskowitz A, Galasso N, Ganesan N, van der Weyden C, Ruan J, Prince HM, Trotman J, Advani R, Dogan A, Horwitz S. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Blood advances. 2020. PMID: 33002132

Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL. Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation. Journal of geriatric oncology. 2020. PMID: 33059999

Hala Borno, Sylvia Zhang, Elena Nieves, Dana Dornsife, Robert G. Johnson, Darcy V. Spicer. Utilization of a multisite financial reimbursement program to promote racial/ethnic diversity and inclusion in therapeutic cancer clinical trials: The iMPACT Study. Journal of Clinical Oncology. 2020. PMID:

Dreyer SB, Upstill-Goddard R, Paulus-Hock V, Paris C, Lampraki EM, Dray E, Serrels B, Caligiuri G, Rebus S, Plenker D, Galluzzo Z, Brunton H, Cunningham R, Tesson M, Nourse C, Bailey UM, Jones M, Moran-Jones K, Wright DW, Duthie F, Oien K, Evers L, McKay CJ, McGregor GA, Gulati A, Brough R, Bajrami I, Pettitt S, Dziubinski ML, Candido J, Balkwill F, Barry ST, Grützmann R, Rahib L, Glasgow Precision Oncology Laboratory,, Australian Pancreatic Cancer Genome Initiative, Johns A, Pajic M, Froeling FEM, Beer P, Musgrove EA, Petersen GM, Ashworth A, Frame MC, Crawford HC, Simeone DM, Lord C, Mukhopadhyay D, Pilarsky C, Tuveson DA, Cooke SL, Jamieson NB, Morton JP, Sansom OJ, Bailey PJ, Biankin AV, Chang DK. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology. 2020. PMID: 33039466

Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. The oncologist. 2020. PMID: 32955138

Buckle GC, Mahapatra R, Mwachiro M, Akoko L, Mmbaga EJ, White RE, Bent S, Van Loon K. Optimal management of esophageal cancer in Africa: A systemic review of treatment strategies. International journal of cancer. 2020. PMID: 32930395

Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. The Lancet. Oncology. 2020. PMID: 33035459

Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M, ExteNET Study Group. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clinical breast cancer. 2020. PMID: 33183970

Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nature medicine. 2020. PMID: 33020646

Hala Borno. Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer. . 2020. PMID:

Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Science immunology. 2020. PMID: 33008914

Mouhieddine TH, Parekh S, Cho HJ, Richter J, DeCastro A, Shah J, Landesman Y, Chari A, Jagannath S, Madduri D. Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma. Annals of hematology. 2020. PMID: 33009581

Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Magbanua MJM, O'Grady N, Hirst G, I-SPY 2 TRIAL Investigators, Asare S, Tripathy D, Berry D, Esserman L, Chien AJ, Petricoin EF, van 't Veer L. Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial. NPJ breast cancer. 2020. PMID: 33083527

James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clinical pharmacokinetics. 2020. PMID: 32304015

Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. Volume 6 of Issue 10 JAMA oncology. 2020. PMID: 32880601